R-MA regimen: Difference between revisions
No edit summary |
|||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AV}} | {{CMG}}; {{AE}} {{AV}} | ||
{{SK}} | {{SK}} Rituximab-Methotrexate-Cytarabine (Ara C) regimen | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of | {{PAGENAME}} refers to a regimen consisting of [[rituximab]], [[methotrexate]], and [[Cytarabine|cytarabine (Ara C)]] used to treat [[mantle cell lymphoma]].<ref name="pmid23504948">{{cite journal| author=Bernstein SH, Epner E, Unger JM, Leblanc M, Cebula E, Burack R et al.| title=A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. | journal=Ann Oncol | year= 2013 | volume= 24 | issue= 6 | pages= 1587-93 | pmid=23504948 | doi=10.1093/annonc/mdt070 | pmc=PMC3660082 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23504948 }} </ref> | ||
==Regimen== | ==Regimen== | ||
| Line 16: | Line 16: | ||
==Indications== | ==Indications== | ||
* [[Mantle cell lymphoma]]<ref name="pmid23504948">{{cite journal| author=Bernstein SH, Epner E, Unger JM, Leblanc M, Cebula E, Burack R et al.| title=A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. | journal=Ann Oncol | year= 2013 | volume= 24 | issue= 6 | pages= 1587-93 | pmid=23504948 | doi=10.1093/annonc/mdt070 | pmc=PMC3660082 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23504948 }} </ref> | |||
==References== | ==References== | ||
Latest revision as of 17:49, 31 March 2015
|
WikiDoc Resources for R-MA regimen |
|
Articles |
|---|
|
Most recent articles on R-MA regimen Most cited articles on R-MA regimen |
|
Media |
|
Powerpoint slides on R-MA regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on R-MA regimen at Clinical Trials.gov Clinical Trials on R-MA regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on R-MA regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on R-MA regimen Discussion groups on R-MA regimen Patient Handouts on R-MA regimen Directions to Hospitals Treating R-MA regimen Risk calculators and risk factors for R-MA regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for R-MA regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Rituximab-Methotrexate-Cytarabine (Ara C) regimen
Overview
R-MA regimen refers to a regimen consisting of rituximab, methotrexate, and cytarabine (Ara C) used to treat mantle cell lymphoma.[1]
Regimen
RRituximab
MMethotrexate
ACytarabine (Ara-C)
Indications
References
- ↑ 1.0 1.1 Bernstein SH, Epner E, Unger JM, Leblanc M, Cebula E, Burack R; et al. (2013). "A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213". Ann Oncol. 24 (6): 1587–93. doi:10.1093/annonc/mdt070. PMC 3660082. PMID 23504948.